Resona Asset Management Co. Ltd. lowered its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 1.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 780,662 shares of the company’s stock after selling 13,087 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Merck & Co., Inc. were worth $114,087,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in MRK. E Fund Management Hong Kong Co. Ltd. grew its holdings in shares of Merck & Co., Inc. by 90.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 1,784 shares of the company’s stock worth $259,000 after purchasing an additional 845 shares during the last quarter. Sumitomo Life Insurance Co. increased its stake in shares of Merck & Co., Inc. by 150.5% in the third quarter. Sumitomo Life Insurance Co. now owns 57,534 shares of the company’s stock valued at $8,360,000 after buying an additional 34,566 shares during the period. Clal Insurance Enterprises Holdings Ltd raised its holdings in Merck & Co., Inc. by 69.5% in the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 222 shares of the company’s stock valued at $32,000 after buying an additional 91 shares during the last quarter. TIAA CREF Individual & Institutional Services LLC raised its holdings in Merck & Co., Inc. by 10.4% in the 3rd quarter. TIAA CREF Individual & Institutional Services LLC now owns 128,498 shares of the company’s stock valued at $18,672,000 after buying an additional 12,109 shares during the last quarter. Finally, Whittier Trust Co. raised its holdings in Merck & Co., Inc. by 1.8% in the 3rd quarter. Whittier Trust Co. now owns 602,983 shares of the company’s stock valued at $87,794,000 after buying an additional 10,512 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.
Key Merck & Co., Inc. News
Here’s some of the latest news about MRK:
- Positive Sentiment: Merck said its TroFuse-015 trial of sac-TMT met its primary overall-survival endpoint in patients with advanced gastroesophageal adenocarcinoma who had received at least two prior lines of treatment. The result adds encouraging evidence for a potential oncology product. Reuters: Merck's drug prolongs survival in advanced stomach, esophageal cancers in trial
- Positive Sentiment: A German court overturned an injunction that had restricted Merck from distributing and offering Keytruda SC in Germany. The ruling removes an immediate obstacle to the formulation, although Halozyme says it will pursue a new patent lawsuit. Zacks: HALO Faces Legal Setback in Germany Over MRK's Keytruda SC
- Neutral Sentiment: Zacks Research raised its rating on Merck from “strong sell” to “hold,” a modest improvement in analyst sentiment rather than a bullish endorsement. MarketBeat: Zacks Research stock recommendations
Insider Activity
In related news, EVP Richard Deluca sold 58,185 shares of the stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $148.01, for a total transaction of $8,611,961.85. Following the transaction, the executive vice president directly owned 112,955 shares of the company’s stock, valued at $16,718,469.55. This represents a 34.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.17% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
MRK has been the topic of a number of research reports. Scotiabank boosted their target price on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the stock a “sector outperform” rating in a report on Tuesday, September 29th. Weiss Ratings raised shares of Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 25th. Daiwa Securities Group raised shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price target for the company in a research note on Wednesday, August 12th. BMO Capital Markets lifted their price target on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday, August 20th. Finally, Zacks Research raised shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $155.74.
Merck & Co., Inc. Stock Up 0.6%
Shares of Merck & Co., Inc. stock opened at $133.56 on Friday. The stock’s 50-day moving average is $145.28 and its 200 day moving average is $129.29. Merck & Co., Inc. has a one year low of $95.36 and a one year high of $156.92. The firm has a market cap of $329.26 billion, a price-to-earnings ratio of 137.69, a PEG ratio of 6.62 and a beta of 0.13. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.35 and a quick ratio of 1.14.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The business had revenue of $18.09 billion during the quarter, compared to the consensus estimate of $17.33 billion. During the same period in the previous year, the company posted $2.58 earnings per share. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. Equities research analysts anticipate that Merck & Co., Inc. will post 2.82 EPS for the current year.
Merck & Co., Inc. Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, January 8th. Investors of record on Tuesday, December 15th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Tuesday, December 15th. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.85. Merck & Co., Inc.’s dividend payout ratio is presently 350.52%.
Merck & Co., Inc. Company Profile
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
See Also
- Five stocks we like better than Merck & Co., Inc.
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
